Oncology / Haematology
Phase III double-blind randomised placebo controlled trial of Atezolizumab in combination with Paclitaxel and Carboplatin in women with advanced/recurrent endometrial cancer.
|Trial Name: AtTEnd||PI: Dr Yoland Antill|
Who can take part:
- Patients with Newly diagnosed, histologically-confirmed with residual disease after surgery either measurable or evaluable, or inoperable stage III-IV endometrial carcinoma/carcinosarcoma after diagnostic biopsy, and naïve to first line systemic anticancer treatment.
- Any previous malignancy within the last 5 years
- Patients with uterine leyomiosarcoma.
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti−PD1, or anti−PDL1 therapeutic antibodies or anti-CTLA4
For further information please contact Judi Clarke – 03 9784 8301
Non-drug Phase 1 Phase 2 Phase 3 Phase 4